The FDA has accepted a biologics license application for Blenrep plus bortezomib or pomalidomide for patients with relapsed ...

在抗肿瘤药物研发的复杂舞台上，Blenrep的故事宛如一出跌宕起伏的戏剧。曾几何时，这款靶向BCMA的抗体药物被视为GSK重返癌症领域的利器，然而，市场的残酷和临床试验的不确定性让它经历了一波三折的命运。对于许多人来说，Blenrep的退市似乎意味着它的终章，但就在GSK即将放弃时，新的希望又重新燃起。在临床试验DREAMM-7的中期分析显示出积极结果时，这款产品又重新回到了公众的视野中。

【葛兰素史克抗癌药物Blenrep显著降低死亡风险 有望重获监管批准】葛兰素史克公司表示，其血液癌症药物在与另一种癌症治疗药物联合使用 ...

第15届医博会期间，同写意生物医药新基建链盟将举办ADC专场，邀请抗体/ADC研发端、生产端和供应链端的企业负责人与会深度交流，帮助行业优化和提升生物药创新生态链。

葛兰素史克称，Blenrep在与另一种名为BorDex的癌症疗法联合使用时，帮助那些骨髓瘤复发的患者们延长了寿命。这家英国制药巨头表示，后期临床试验 ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks to a key patient survival win. The antibody-drug conjugate (ADC ...

Blenrep plus Velcade and dexamethasone significantly improves overall survival in relapsed/refractory multiple myeloma compared to Darzalex-based regimens. The DREAMM-7 trial met its secondary ...

The trial evaluated Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex. A pre-specified interim ...

GSK plc GSK announced that the FDA accepted its biologics license application (BLA) seeking approval for the Blenrep ...

GSK has great expectations for its BCMA-directed cancer drug Blenrep, but a failed phase 3 trial in relapsed or refractory multiple myeloma has raised doubts about its prospects – and even the ...